Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
You may also be interested in...
More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.